Heart failure with preserved ejection fraction: the diagnosis that's easy to miss

Ejection fraction — the percentage of blood the left ventricle pumps out with each contraction — is the number most people associate with heart failure diagnosis, and a normal ejection fraction is sometimes mistakenly treated as ruling heart failure out entirely. Heart failure with preserved ejection fraction is the diagnosis that directly contradicts that assumption: the heart's pumping percentage looks normal, but the heart muscle has become stiffer and less able to relax and fill properly between beats, producing the same fluid backup and breathlessness symptoms as more familiar reduced-ejection-fraction heart failure.

This distinction — a pumping problem versus a filling and relaxation problem — is genuinely different at the mechanical level, and it's part of why HFpEF is more challenging to diagnose confidently than reduced-ejection-fraction heart failure: the standard echocardiogram number that flags the more familiar form doesn't flag HFpEF the same way, requiring a physician to look more specifically at diastolic function measures and other supporting evidence rather than relying on ejection fraction alone.

HFpEF is also more strongly associated with a specific risk factor profile than reduced-ejection-fraction heart failure: hypertension, obesity, diabetes, and older age all correlate more strongly with HFpEF, and its prevalence has been rising alongside rising rates of these underlying conditions in the general population — a pattern that's made HFpEF an increasing focus of cardiology research and treatment guideline development in recent years, since it wasn't clearly recognized as its own distinct category as early or as clearly as reduced-ejection-fraction heart failure was.

Treatment approaches for HFpEF have historically lagged behind the more established reduced-ejection-fraction heart failure treatment protocols, in part because many medications that clearly help the reduced-ejection-fraction form haven't shown the same clear benefit for HFpEF's different underlying mechanism — though specific treatment options with genuine supporting evidence for HFpEF have expanded meaningfully in recent years, which is one more reason correctly distinguishing the two forms matters directly for getting the right treatment rather than assuming a generic heart failure protocol applies equally to both.